[
  {
    "ts": null,
    "headline": "Correction to Gilead Sciences Veklury Sales Guidance Headline on Feb. 11",
    "summary": "Gilead Sciences sees 2025 Veklury sales of $1.4 billion. Gilead Sciences Sees 2205 Veklury Sales $1.4B >GILD, at 4:02 p.m. ET on Feb. 11, misstated the year in the headline. ...",
    "url": "https://finnhub.io/api/news?id=39a440c6f2a667620b79df53d6d815f476c63b31bc8960b17f1c9009b4b6dc42",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745344440,
      "headline": "Correction to Gilead Sciences Veklury Sales Guidance Headline on Feb. 11",
      "id": 134037371,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences sees 2025 Veklury sales of $1.4 billion. Gilead Sciences Sees 2205 Veklury Sales $1.4B >GILD, at 4:02 p.m. ET on Feb. 11, misstated the year in the headline. ...",
      "url": "https://finnhub.io/api/news?id=39a440c6f2a667620b79df53d6d815f476c63b31bc8960b17f1c9009b4b6dc42"
    }
  },
  {
    "ts": null,
    "headline": "Gilead reports topline data from Phase III trial of Trodelvy combo therapy",
    "summary": "In the trial, the primary endpoint was met, demonstrating a PFS improvement against standard treatment.",
    "url": "https://finnhub.io/api/news?id=1261358b5102ce096f028a17d36cf904e79ede165fdb88efa0fce36316f36526",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745332103,
      "headline": "Gilead reports topline data from Phase III trial of Trodelvy combo therapy",
      "id": 134039003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In the trial, the primary endpoint was met, demonstrating a PFS improvement against standard treatment.",
      "url": "https://finnhub.io/api/news?id=1261358b5102ce096f028a17d36cf904e79ede165fdb88efa0fce36316f36526"
    }
  },
  {
    "ts": null,
    "headline": "Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?",
    "summary": "We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other cheap NASDAQ stocks. On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an […]",
    "url": "https://finnhub.io/api/news?id=2b75d494b18097f741d552b21ff4a804c33b124f066710a81782bb2637170715",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745329942,
      "headline": "Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?",
      "id": 134039004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other cheap NASDAQ stocks. On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an […]",
      "url": "https://finnhub.io/api/news?id=2b75d494b18097f741d552b21ff4a804c33b124f066710a81782bb2637170715"
    }
  },
  {
    "ts": null,
    "headline": "Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy",
    "summary": "Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.",
    "url": "https://finnhub.io/api/news?id=fb797e9d859b02cce2cfd30df698c57a5a3a2d8623dade1fe4a1f6047414ee40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745329681,
      "headline": "Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy",
      "id": 134038510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.",
      "url": "https://finnhub.io/api/news?id=fb797e9d859b02cce2cfd30df698c57a5a3a2d8623dade1fe4a1f6047414ee40"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?",
    "summary": "Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=fc7284558b260b2aa35915f10fea13d539f12765babd08abe505f1f79771400b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745327160,
      "headline": "Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?",
      "id": 134038512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=fc7284558b260b2aa35915f10fea13d539f12765babd08abe505f1f79771400b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
    "summary": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
    "url": "https://finnhub.io/api/news?id=08b81e1f1ee07ec4d392433efa7f8f457ff7d36b2ef5676d47f018977cdeeae4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745320380,
      "headline": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
      "id": 134146414,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
      "url": "https://finnhub.io/api/news?id=08b81e1f1ee07ec4d392433efa7f8f457ff7d36b2ef5676d47f018977cdeeae4"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences - Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients with Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer",
    "summary": "FOSTER CITY - Gilead Sciences, Inc. today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy plus Keytruda significantly improved...",
    "url": "https://finnhub.io/api/news?id=9a5cf79edcea3e66635dcd7f020e882773dc493146581da4a36888bf26b11ad5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745318829,
      "headline": "Gilead Sciences - Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients with Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer",
      "id": 134033680,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "FOSTER CITY - Gilead Sciences, Inc. today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy plus Keytruda significantly improved...",
      "url": "https://finnhub.io/api/news?id=9a5cf79edcea3e66635dcd7f020e882773dc493146581da4a36888bf26b11ad5"
    }
  },
  {
    "ts": null,
    "headline": "Biomedical HIV Prevention Summit in Atlanta Is the Focus To Drive Meaningful Action With Gilead Sciences",
    "summary": "This year's Biomedical HIV Prevention Summit in Atlanta emphasized the importance of advancing prevention in the U.S. South, a region disproportionately impacted by HIV. We joined advocates, community...",
    "url": "https://finnhub.io/api/news?id=fdd761c9ebd10cf2c068715bb5d8cad16c08889b916fc58ddbae4737530c1fd9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745315048,
      "headline": "Biomedical HIV Prevention Summit in Atlanta Is the Focus To Drive Meaningful Action With Gilead Sciences",
      "id": 134033281,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "This year's Biomedical HIV Prevention Summit in Atlanta emphasized the importance of advancing prevention in the U.S. South, a region disproportionately impacted by HIV. We joined advocates, community...",
      "url": "https://finnhub.io/api/news?id=fdd761c9ebd10cf2c068715bb5d8cad16c08889b916fc58ddbae4737530c1fd9"
    }
  },
  {
    "ts": null,
    "headline": "Polaris Global Equity Composite Q1 2025 Commentary",
    "summary": "Polaris Global Equity Composite Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=708da320ab507a8e11dc24e2827b42a1cdfdb1820663116abea6aab0aa95dfa7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745292420,
      "headline": "Polaris Global Equity Composite Q1 2025 Commentary",
      "id": 134030042,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=708da320ab507a8e11dc24e2827b42a1cdfdb1820663116abea6aab0aa95dfa7"
    }
  }
]